CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
We began operating in 1947 and, since then, have undergone several changes to our business structure. Charles River Laboratories International, Inc. was incorporated in 1994 and we completed our initial public offering in 2000. Our stock is traded on the New York Stock Exchange under the symbol "CRL" and is included in the Standard & Poor's 500 and Composite 1500 indices, the New York Stock Exchange (NYSE) Arca Biotechnology Index, the NYSE Composite and many of the Russell indices, among others. We are headquartered in Wilmington, Massachusetts. Our headquarters mailing address is 251 Ballardvale Street, Wilmington, MA, 01887, and the telephone number at that location is (781) 222-6000. Our Internet site is www.criver.com. Material contained on our Internet site is not incorporated by reference into this Form 10-K. Unless the context otherwise requires, references in this Form 10-K to "Charles River," "we," "us," "the Company" or "our" refer to Charles River Laboratories International, Inc. and its subsidiaries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B |
| Cost of revenue | — | — | — | — | — | — | — | — | $865.6M | $757.7M |
| Gross profit | — | — | — | — | — | — | — | — | $992.0M | $923.7M |
| SG&A | $743.1M | $751.0M | $747.9M | $665.1M | $619.9M | $528.9M | $517.6M | $443.9M | $371.3M | $364.7M |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M | $432.7M | $351.2M | $331.4M | $288.3M | $237.6M |
| Interest expense | $107.0M | $126.3M | $136.7M | $59.3M | $73.9M | $86.4M | $60.9M | $63.8M | $29.8M | $27.7M |
| Pre-tax income | -$99.5M | $93.1M | $581.3M | $623.0M | $480.7M | $447.1M | $304.1M | $281.7M | $297.0M | $222.9M |
| Income tax | $42.7M | $67.8M | $100.9M | $130.4M | $81.9M | $81.8M | $50.0M | $54.5M | $171.4M | $66.8M |
| Net income | -$144.3M | $22.2M | $474.6M | $486.2M | $391.0M | $364.3M | $252.0M | $226.4M | $123.4M | $154.8M |
| EPS, basic | -2.91 | 0.20 | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 |
| EPS, diluted | -2.91 | 0.20 | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 | 3.23 |
| Shares, diluted (wtd. avg.) | $49.6M | $51.6M | $51.5M | $51.3M | $51.4M | $50.6M | $49.7M | $49.0M | $48.6M | $48.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $213.8M | $194.6M | $284.5M | $241.2M | $246.3M | $233.1M | $240.0M | $197.3M | $166.3M | $119.9M |
| Short-term investments | — | — | — | — | $1.1M | $1.0M | $941.0K | $885.0K | $28.5M | $3.8M |
| Receivables | $708.9M | $720.9M | $780.4M | $752.4M | $642.9M | $617.7M | $514.0M | $472.2M | $430.0M | $364.1M |
| Inventory | $299.1M | $278.5M | $380.3M | $255.8M | $199.1M | $185.7M | $160.7M | $127.9M | $115.0M | $95.8M |
| Total current assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $897.8M | $826.6M | $656.8M |
| Property, plant and equipment | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $932.9M | $782.0M | $755.8M |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $804.9M | $787.5M |
| Other intangibles | $340.0M | $723.4M | $864.1M | $955.3M | $1.06B | $787.6M | $689.4M | $610.9M | $369.8M | $394.4M |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B |
| Accounts payable | $148.8M | $140.3M | $168.9M | $205.9M | $198.1M | $122.5M | $111.5M | $66.2M | $77.8M | $68.5M |
| Short-term debt | $166.0K | $155.0K | $3.2M | $1.3M | $101.0K | $47.2M | $35.5M | $28.2M | $28.5M | $24.6M |
| Total current liabilities | $1.12B | $994.1M | $1.06B | $1.09B | $1.03B | $839.8M | $710.2M | $558.2M | $463.5M | $429.6M |
| Long-term debt | — | — | — | — | — | — | — | $1.63B | $1.09B | $1.19B |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B |
| Retained earnings | $1.39B | $1.81B | $1.89B | $1.43B | $980.8M | $625.4M | $280.3M | $42.1M | $288.7M | $165.3M |
| Total equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.54B | $2.12B | $1.64B | $1.32B | $1.05B | $839.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M | $546.6M | $480.9M | $441.1M | $318.1M | $316.9M |
| Depreciation and amortisation | $403.3M | $361.7M | $314.1M | $303.9M | $265.5M | $234.9M | $198.1M | $161.8M | $131.2M | $126.7M |
| Stock-based compensation | $71.1M | $69.9M | $72.0M | $73.6M | $71.5M | $56.3M | $57.3M | $47.3M | $44.0M | $43.6M |
| Capital expenditure | $219.2M | $233.0M | $318.5M | $324.7M | $228.8M | $166.6M | $140.5M | $140.1M | $82.4M | $55.3M |
| Investing cash flow | -$209.3M | -$245.1M | -$563.2M | -$607.9M | -$1.44B | -$601.5M | -$681.5M | -$955.0M | -$72.6M | -$692.7M |
| Financing cash flow | -$536.7M | -$550.9M | -$85.5M | -$42.4M | $672.6M | $47.2M | $231.9M | $558.1M | -$208.5M | $380.8M |
| Buybacks | $360.7M | $119.2M | $24.2M | $38.7M | $40.7M | $24.0M | $18.1M | $13.8M | $106.9M | $12.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001100682-26-000022.
Others in SIC 8731
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $44.69B | 34.2x | 5.9% |
| INCY | INCYTE CORP | $25.32B | 19.8x | 21.2% |
| MEDP | Medpace Holdings, Inc. | $16.50B | 38.7x | 20.0% |
| ABSI | Absci Corp | $1.51B | — | -38.2% |
| OABI | OmniAb, Inc. | $629.5M | — | -29.3% |
| NRC | NRC HEALTH | $476.2M | 0.4x | -4.0% |
| MXCT | MAXCYTE, INC. | $132.1M | — | -5.7% |
| BIAF | bioAffinity Technologies, Inc. | $123.7M | — | -34.2% |